Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP26A1 | O43174 | 1/20 | 0.53 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.47 |
| ▸ | CA1 | P00915 | 3/20 | 0.44 |
| ▸ | CA2 | P00918 | 3/20 | 0.44 |
| ▸ | ACHE | P22303 | 3/20 | 0.44 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.43 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.43 |
| ▸ | RELA | Q04206 | 1/20 | 0.43 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.42 |
| ▸ | SLC5A1 | P13866 | 1/20 | 0.42 |
| ▸ | SLC5A2 | P31639 | 1/20 | 0.42 |
| ▸ | DRD2 | P14416 | 2/20 | 0.41 |
| ▸ | DRD3 | P35462 | 2/20 | 0.41 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.41 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.41 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4622326 | 0.81 | CYP26A1 (0.58) | CYP26A1CYP19A1CA1CA2ACHE | |
| SCHEMBL4622590 | 0.79 | CYP26A1 (0.56) | CYP26A1CYP19A1CA1CA2ACHE | |
| SCHEMBL4621232 | 0.78 | CA1 (0.57) | CYP26A1CYP19A1CA1CA2ACHE | |
| SCHEMBL4622235 | 0.76 | CA1 (0.55) | CYP26A1CYP19A1CA1CA2ACHE | |
| SCHEMBL3412561 | 0.74 | SLC5A1 (0.46) | CYP26A1CYP19A1NFKB1NFKB2RELA | |
| SCHEMBL4621033 | 0.74 | CYP26A1 (0.61) | CYP26A1CYP19A1CA1CA2ACHE | |
| SCHEMBL8042881 | 0.73 | CYP26A1 (0.55) | CYP26A1CYP19A1CA1CA2ACHE | |
| SCHEMBL4623036 | 0.73 | CYP26A1 (0.67) | CYP26A1CYP19A1CA1CA2ACHE | |
| SCHEMBL7288575 | 0.73 | CYP26A1 (0.67) | CYP26A1CYP19A1CA1CA2ACHE | |
| SCHEMBL2305878 | 0.72 | CYP26A1 (0.56) | CYP26A1CYP19A1CA1CA2ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7816331-B2 | Substituted indazole-O-glucosides | JANSSEN PHARMACEUTICA NV (BE) | 2010-10-19 | — | — | US | disclosed |
| US-20100062971-A1 | SUBSTITUTED INDAZOLE-O-GLUCOSIDES | PATEL MONA | 2010-03-11 | — | — | US | disclosed |
| EP-1680414-A4 | SUBSTITUTED INDAZOLE-O-GLUCOSIDES | JANSSEN PHARMACEUTICA NV (BE) | 2009-05-27 | — | — | EP | disclosed |
| US-20090099104-A1 | SUBSTITUTED INDAZOLES-O- GLUCOSIDES | PATEL MONA | 2009-04-16 | — | — | US | disclosed |
| US-7511021-B2 | Substituted indazole-O-glucosides | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-03-31 | — | — | US | disclosed |
| US-20060217323-A1 | Substituted indazole-O-glucosides | Tanabe Pharma Corporation (JP) | 2006-09-28 | — | — | US | disclosed |
| US-7084124-B2 | Substituted indazole-O-glucosides | JANSSEN PHARMACEUTICA, N.V. (BE) | 2006-08-01 | — | — | US | disclosed |
| EP-1680414-A2 | SUBSTITUTED INDAZOLE-O-GLUCOSIDES | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-07-19 | — | — | EP | disclosed |
| US-20050032711-A1 | Substituted indazole-O-glucosides | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-02-10 | — | — | US | disclosed |
| WO-2005011592-A2 | SUBSTITUTED INDAZOLE-O-GLUCOSIDES | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-02-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050032711-A1 | Substituted indazole-O-glucosides | GYS2, GPR119, UGGT1 | CYP26A1 455/4885CYP19A1 232/4885CA1 4694/4885 |
| US-20100062971-A1 | SUBSTITUTED INDAZOLE-O-GLUCOSIDES | GYS2, GPR119, UGGT1 | CYP26A1 455/4885CYP19A1 232/4885CA1 4694/4885 |
| US-20090099104-A1 | SUBSTITUTED INDAZOLES-O- GLUCOSIDES | GYS2, GPR119, PYGL | CYP26A1 438/4885CYP19A1 228/4885CA1 4655/4885 |
| US-20060217323-A1 | Substituted indazole-O-glucosides | GYS2, GPR119, UGGT1 | CYP26A1 455/4885CYP19A1 232/4885CA1 4694/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.